心脏骤停后较高与较低血压目标:系统评价与个体患者数据Meta分析
该系统评价与个体患者数据Meta分析检索多个数据库,纳入4项随机对照试验共1087例心脏骤停后复苏患者,比较较高MAP目标(≥71 mmHg)与较低MAP目标(≤70 mmHg)。主要终点180天全因死亡RR 1.08(95%CI 0.92-1.26),神经功能不良恢复RR 1.01(95%CI 0.86-1.19),两组严重不良事件无差异。试验序贯分析可排除25%或以上的治疗效应(RR<0.75)。结论认为较高MAP目标不太可能降低死亡率或改善神经功能,未来需研究是否存在相关但较小的治疗效应。
要点
- 心脏骤停后复苏患者,较高MAP目标(≥71 mmHg)与较低MAP目标(≤70 mmHg)相比,180天全因死亡RR 1.08(95%CI 0.92-1.26),无统计学显著差异。
- 神经功能不良恢复(mRS 4-6或CPC 3-5)在较高MAP组与较低MAP组相比RR 1.01(95%CI 0.86-1.19),无统计学显著差异。
- 两组严重不良事件无差异,较高MAP目标未增加不良效应。
- 试验序贯分析可排除25%或以上治疗效应(RR<0.75),但较低的相关治疗效应仍需未来研究。
- 指南推荐心脏骤停后目标MAP>65 mmHg,本分析中较高MAP目标为≥71 mmHg、较低为≤70 mmHg。
适用人群与场景
- 心脏骤停后复苏的患者,纳入随机分至较高MAP目标(≥71 mmHg)或较低MAP目标(≤70 mmHg)的临床试验人群。
诊断标准与关键阈值
- 较高MAP目标定义为≥71 mmHg,较低MAP目标定义为≤70 mmHg。
- 神经功能不良恢复定义为改良Rankin评分4-6分或脑功能分类评分3-5分。
研究设计与关键结果
- 研究类型为系统评价与个体患者数据Meta分析,纳入4项随机对照试验,共1087例患者,所有试验偏倚风险低(RoB 2评估)。
- 主要终点180天全因死亡:较高MAP组 vs 较低MAP组 RR 1.08(95%CI 0.92-1.26)。
- 主要终点神经功能不良恢复:较高MAP组 vs 较低MAP组 RR 1.01(95%CI 0.86-1.19)。
- 试验序贯分析显示可排除25%或以上治疗效应(RR<0.75)。
- 两组严重不良事件无差异。
证据类型、等级与局限
- 证据类型:系统评价与个体患者数据Meta分析,纳入4项随机对照试验,所有试验偏倚风险低(RoB 2)。
- 局限:仅能排除25%或以上治疗效应(RR<0.75),未来需研究是否存在相关但较低的治疗效应。
对床旁实践的改变
- 对于心脏骤停后复苏患者, targeting 较高MAP(≥71 mmHg)与较低MAP(≤70 mmHg)相比,不太可能降低死亡率或改善神经功能恢复,且未增加不良效应。
- 指南推荐心脏骤停后目标MAP>65 mmHg;本分析结果不支持将MAP目标常规提高至≥71 mmHg以改善预后。
指南或共识出处
- 指南推荐心脏骤停后目标平均动脉压>65 mmHg(原文引用指南,未注明具体指南名称)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Guidelines recommend targeting mean arterial pressure (MAP) > 65 mmHg in patients after cardiac arrest (CA). Recent trials have studied the effects of targeting a higher MAP as compared to a lower MAP after CA. We performed a systematic review and individual patient data meta-analysis to investigate the effects of higher versus lower MAP targets on patient outcome.
METHOD: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, LILACS, BIOSIS, CINAHL, Scopus, the Web of Science Core Collection, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry, Google Scholar and the Turning Research into Practice database to identify trials randomizing patients to higher (≥71 mmHg) or lower (≤70 mmHg) MAP targets after CA and resuscitation. We used the Cochrane Risk of Bias tool, version 2 (RoB 2) to assess for risk of bias. The primary outcomes were 180-day all-cause mortality and poor neurologic recovery defined by a modified Rankin score of 4-6 or a cerebral performance category score of 3-5.
RESULTS: Four eligible clinical trials were identified, randomizing a total of 1,087 patients. All the included trials were assessed as having a low risk for bias. The risk ratio (RR) with 95% confidence interval for 180-day all-cause mortality for a higher versus a lower MAP target was 1.08 (0.92-1.26) and for poor neurologic recovery 1.01 (0.86-1.19). Trial sequential analysis showed that a 25% or higher treatment effect, i.e., RR < 0.75, can be excluded. No difference in serious adverse events was found between the higher and lower MAP groups.
CONCLUSIONS: Targeting a higher MAP compared to a lower MAP is unlikely to reduce mortality or improve neurologic recovery after CA. Only a large treatment effect above 25% (RR < 0.75) could be excluded, and future studies are needed to investigate if relevant but lower treatment effect exists. Targeting a higher MAP was not associated with any increase in adverse effects.
参考来源
- Niemelä V, Siddiqui F, Ameloot K, et al. Higher versus lower blood pressure targets after cardiac arrest: Systematic review with individual patient data meta-analysis. Resuscitation. 2023. PMID: 37295549. doi:10.1016/j.resuscitation.2023.109862
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。